astrazeneca+sil+presentation

41
7/18/2019 AstraZeneca+SIL+Presentation http://slidepdf.com/reader/full/astrazenecasilpresentation 1/41    ©    A    B    B    G   r   o   u   p   -    1   -    2    1   -    M   a   r   -    0    7 Safety Integrity Level SIL Paul Lucas  ABB Engineering Services 13 mars 2007

Upload: xie-shj

Post on 14-Jan-2016

8 views

Category:

Documents


0 download

DESCRIPTION

AstraZeneca+SIL+Presentation

TRANSCRIPT

Page 1: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 1/41

   ©

   A   B   B   G  r  o  u  p  -   1  -

   2   1  -   M  a  r  -   0   7

Safety Integrity Level

SIL

Paul Lucas

 ABB Engineering Services

13 mars 2007

Page 2: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 2/41

   ©

   A   B   B   G  r  o  u  p  -   2  -

   2   1  -   M  a  r  -   0   7

Agenda

Why do we need SIL systems?

Where does the SIL concept come from?

What is a SIL?

The Three Steps of SIL

Set the target SIL (SIL Determination)

Design to meet the target SIL

Operate and Maintain to keep hitting the target SIL

Page 3: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 3/41

   ©

   A   B   B   G  r  o  u  p  -   3  -

   2   1  -   M  a  r  -   0   7

Why do we need SIL systems?

BP Texas City, USA 2005

Page 4: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 4/41   ©

   A   B   B   G  r  o  u  p  -   4  -

   2   1  -   M  a  r  -   0   7

Why do we need SIL systems?

Buncefield, UK 2006

Page 5: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 5/41

   ©

   A   B   B   G  r  o  u  p  -   5  -

   2   1  -   M  a  r  -   0   7

Safety Issues

How do you demonstrate that your operations are

‘safe’?

How do you demonstrate that your equipment is ‘safe’?

How do you demonstrate that your safety and protectivesystems protect against your hazards?

You can answer these questions by demonstratingcompliance with Industry Safety Standards

Page 6: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 6/41

   ©

   A   B   B   G  r  o  u  p  -   6  -

   2   1  -   M  a  r  -   0   7

Functional Safety Standard - IEC61508

Generic Standard supported by Sector variants

(IEC61511 for Process Sector)

Guidance on use of Electrical, Electronic andProgrammable Electronic Systems which perform safety

functions

Considers the entire Safety Critical Loop Comprehensive approach involving concepts of Safety

Lifecycle and all elements of protective system

Risk-based approach leading to determination of Safety

Integrity Levels - SIL

Page 7: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 7/41

   ©

   A   B   B   G  r  o  u  p  -   7  -

   2   1  -   M  a  r  -   0   7

Generic and Application Sector Standards

I  E  C 6  1 5  0 8 

IEC61511 :Process Sector 

Medical Sector IEC61513 :

Nuclear Sector 

IEC62061 :

Machinery Sector 

Page 8: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 8/41

   ©

   A   B   B   G  r  o

  u  p  -   8  -

   2   1  -   M  a  r  -   0   7

IEC61511 Safety Lifecycle

Design & Development

of other means of risk

reduction

Hazard and Risk Assessment1

Allocation of safety functions

to protection layers2

Safety Requirementsspecification for the safety

instrumented system3

Design & Engineering of

Safety Instrumented System

4

Installation, Commissioning

and Validation5

Operation and Maintenance6

Modification7

Decommissioning8

M an a g em en

 t   of  f   un c t  i   on al   s a

f   e t   y an d f   un c t  i   on

 al   s af   e t   y

 a s s e s sm en t   an d  a u d i   t  i  n g

10

 S  af   e t  

 yL i  f   e- C  y cl   e s t  r  u c t   ur  e an d  pl   anni  n

 g

11

Verification

9

Page 9: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 9/41

   ©

   A   B   B   G  r  o

  u  p  -   9  -

   2   1  -   M  a  r  -   0   7

Step 1 – Set the Target SIL

Design & Development

of other means of risk

reduction

Hazard and Risk Assessment1

Allocation of safety functions

to protection layers2

Safety Requirementsspecification for the safety

instrumented system3

Design & Engineering of

Safety Instrumented System

4

Installation, Commissioning

and Validation5

Operation and Maintenance6

Modification7

Decommissioning8

M an a g em en

 t   of  f   un c t  i   on al   s a

f   e t   y an d f   un c t  i   on

 al   s af   e t   y

 a s s e s sm en t   an d  a u d i   t  i  n g

10

 S  af   e t  

 yL i  f   e- C  y cl   e s t  r  u c t   ur  e an d  pl   anni  n

 g

11

Verification

9

IEC61511 Safety Lifecycle

Page 10: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 10/41

   ©

   A   B   B   G  r  o

  u  p  -   1   0  -

   2   1  -   M  a  r  -   0   7

Hazard and Risk Assessment

Trevor Kletz (safety guru) sums it up as: -

How big

How often

So what?

What are the hazardous events – the consequence

How often may they occur – the frequency

Risk = Consequence * Frequency

Is this unacceptable to the company/ regulator/ society?

What is risk is tolerated?

Page 11: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 11/41

   ©

   A   B   B   G  r  o

  u  p  -   1   1  -

   2   1  -   M  a  r  -   0   7

Tolerable Risk and ALARP

Intolerable

Broadly Acceptable

Risk cannot be justified on anygrounds

May be “Tolerable” if risk level is

 As Low As Reasonably

Practicable (ALARP)

No need for detailed working todemonstrate ALARP

ALARP or

Tolerability

Band

 ALARP = As Low As Reasonably Practicable

Low Risk

High Risk

Page 12: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 12/41

   ©

   A   B   B   G  r  o

  u  p  -   1   2  -

   2   1  -   M  a  r  -   0   7

Risk Reduction to meet tolerable risk

Residual

riskResidual

risk

Process

RiskProcess

Risk

Risk

TargetRisk

Target

Increasing

riskNecessary risk reduction

Actual risk reduction

Risk reduction

from all

Non-Instrumented

Prevention /Mitigation Measures

Risk reduction

from all

Non-InstrumentedPrevention /

Mitigation Measures

Risk reduction

from Safety

InstrumentedFunction (SIF)

Risk reduction

from Safety

InstrumentedFunction (SIF)

SIL

Page 13: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 13/41

   ©

   A   B   B   G  r  o

  u  p  -   1   3  -

   2   1  -   M  a  r  -   0   7

Expressing SIL

SIL 1

SIL 2

SIL 3

SIL 4

Risk

Reduction

Probability of failure

on demand (PFD)

0.1 to 0.01

0.01 to 0.001

0.001 to 0.0001

0.0001 to 0.00001

10 – 100

100 – 1000

1000 –

10000

10000 -

100000

Page 14: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 14/41

   ©

   A   B   B   G  r  o

  u  p  -   1   4  -

   2   1  -   M  a  r  -   0   7

Methods for SIL Determination

Safety Layer Matrix

IEC 61511-3 Annex C

Risk Graphs

IEC 61511-3 Annex D

Layer of Protection Analysis (LOPA)

IEC 61511-3 Annex F

Fault Tree Analysis

IEC 61511-3 Annex B

Page 15: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 15/41

   ©

   A   B   B   G  r  o

  u  p  -   1   5  -

   2   1  -   M  a  r  -   0   7

W3

Pa

Pb

Pa

Fa

Fb

Fb

Fa

Cc

Cd

Ce

Ca

Pb

W2 W1

SIL 1

SIL 2

SIL 3

SIL 4

Extent of Damage

Proportion of Time of Exposure to Hazard

Mitigating Factors

Prob or Freq of Hazardous Event

Cb = Lost time injury

Cc = Major Injury

Cd = On-site fatality

Ce = Multiple on-site fatalities or one

off-site fatality

Fa = Low (< 0.1)

Fb = High (> 0.1)

Pa = Good Chance of Avoiding

Consequences (> 90%)

Pb = Poor Chance of Avoiding

Consequences (< 10%)

W1= Very Low (F < 0.01 / YR)

W2= Low (F > 0.01 / YR)

Ca = Minor Injury

W3= Relatively High (F > 0.1 / YR)

5/9

Risk Graph

Page 16: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 16/41

   ©

   A   B   B   G  r  o

  u  p  -   1   6  -

   2   1  -   M  a  r  -   0   7

Initiating Frequency Intermediate

Cause (/yr) 1 2 3 4 5 6 Event Frequency

 A 0.1 1 0.01 1 0.1 0.0001B 0.1 0.1 0.01 1 0.1 0.00001

C 0.5 0.1 0.01 1 1 0.0005

D

E

F

0.000610.0492

SIL 1

PFDavg Calculation

Total Event Frequency, Fe/yr Maximum PFDavg for Safety Instrumented Function, Ft/Fe

Target Safety Integrity Level

Independent Layer of Protection

LOPA

For each initiating cause, calculate which layers provide

protection

Multiply for Event Frequency

Add for 

Total

Event

Freq

PFD = Target (0.00003) / Total Event (0.00061) = 0.0492

Page 17: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 17/41

   ©

   A   B   B   G  r  o

  u  p  -   1   7  -

   2   1  -   M  a  r  -   0   7

Comparison of Methods

Safety Layer

Matrix

Risk Graph LOPA Fault Tree

 Analysis

Initial Screening R R R NR

Detailed Analysis NR NR R R

Multiple Causes

with Different

Protection

NR NR R R

Potential

DependencyNR NR NR R

Output (SIL or

PFDavg)SIL SIL PFDavg PFDavg

Need to include

specific HumanFactors

NR NR R R

Suitable for SIL 1 1 1 & 2 >1

NR = Not recommended: R = recommended

Page 18: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 18/41

   ©

   A   B   B   G  r  o

  u  p  -   1   8  -

   2   1  -   M  a  r  -   0   7

Summary of Step 1

Get the Target SIL correct

Save time, money, equipment, maintenance

Calibrate any method for YOUR tolerability Use method suitable for the consequences

Page 19: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 19/41

   ©

   A   B   B   G  r  o

  u  p  -   1   9  -

   2   1  -   M  a  r  -   0   7

Step 2 – Design to meet the target SIL

Design & Development

of other means of risk

reduction

Hazard and Risk Assessment1

Allocation of safety functions

to protection layers2

Safety Requirementsspecification for the safety

instrumented system3

Design & Engineering of

Safety Instrumented System

4

Installation, Commissioning

and Validation5

Operation and Maintenance6

Modification7

Decommissioning8

M an a g em en t   of  f   un c t  i   on al   s af   e t   y an d f   un c t  i   on

 al   s af   e t   y

 a s s e s sm en t   an

 d  a u d i   t  i  n g

10

 S  af   e t   yL i  f   e- C  y cl   e s t  r  u c

 t   ur  e an d  pl   anni  n

 g

11

Verification

9

IEC61511 Safety Lifecycle

Page 20: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 20/41

   ©

   A   B   B   G  r  o

  u  p  -   2   0  -

   2   1  -   M  a  r  -   0   7

Random Hardware Failures

 Any item of equipment in a protective system can fail.

There are broadly two types of system failure

Fail Safe

component failure to an open circuit condition, loose connections,

loss of power (air or electrical)

These will cause the system to shut down the plant unnecessarily

but are self revealing and ‘fail safe’.

Fail to Danger 

contacts welding together, instrument or trip valve mechanisms

seizing, impulse lines becoming blocked

These are ‘fail to danger’ because, when a demand occurs, the

system cannot respond i.e. un-revealed failures

These are the failures we need for the PFD calculation

Page 21: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 21/41

   ©

   A   B   B   G  r  o

  u  p  -   2   1  -

   2   1  -   M  a  r  -   0   7

Example

High Pressure Trip Pressure

Transmitter 

Relay

Trip Valve

Solenoid Valve

Trip Amp

Page 22: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 22/41

   ©

   A   B   B   G  r  o

  u  p  -   2   2  -

   2   1  -   M  a  r  -   0   7

A Single Channel System – 6 month testing

Overall dangerous failure rate for the channel is the sumof the rates for the components.

λd = 0.067 + 0.0033 0.033 0.033 = 0.1863 per year  + +

PressureTransmitter 

SolenoidValve

TripValve

RelayTrip Amplifier 

PressureTransmitter 

0.05 +

If this is tested every 6 months then,

PFDavg = ½ x 0.5 x 0.1863 = 0.047

which is near the middle of SIL 1

PFDavg = ½ T x λ d

Page 23: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 23/41

   ©

   A   B   B   G  r  o  u  p  -   2   3  -

   2   1  -   M  a  r  -   0   7

Safety Integrity Level

 Achieved PFDavg

SIL 1 SIL 2 SIL 3 SIL 4

0.01 0.001 0.0001 0.00001

PFDavg = 0.005

0.1

PFDavg = 0.05

10-1

10-2

10-3

10-4

10-5

PFDavg = 0.047

(6 Month test interval)

Th N d F T ti

Page 24: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 24/41

   ©

   A   B   B   G  r  o  u  p  -   2   4  -

   2   1  -   M  a  r  -   0   7

The Need For Testing

Fail to Danger 

contacts welding together, instrument or trip valve mechanisms

seizing, impulse lines becoming blocked These are ‘fail to danger’ because, when a demand occurs, the

system cannot respond i.e. un-revealed failures

Only exposed by testing

Healthy

Faulty

Unrevealed

fault   Demand

Test

TestInterval

DeadTime

Time (years)

Test

x

Test Test Test Test

Testing can expose un-revealed failures

Page 25: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 25/41

   ©

   A   B   B   G  r  o  u  p  -   2   5  -

   2   1  -   M  a  r  -   0   7

Multiple Channels And Common Cause Failure ( )

More complicated – but same principles

For One Channel (1 out of 1)

PFDav1

= 1 / 2 λd

∗ Τ

For Two Channels (1 out of 2)

PFDav2 = 4/3 [ PFDav1 ]2+ β [PFDav1 ] or PFDav2 = 1/3[(λd)

2 ∗ Τ2] + β [PFDav1]

For Three Channels (1 out of 3)

PFDav3 = 2 [PFDav1 ]3 + β [PFDav1 ] or PFDav3 = 1/4[(λd)3 ∗ Τ3] + β [PFDav1 ]

For Two Channels (2 out of 3)

PFDav2 = 4[PFDav1]2 + β [PFDav1 ] or PFDav2 = (λd)

2 * Τ2 + β [PFDav1 ]

Taken From Practical Industrial Safety, Risk Assessment & Shutdown Systems, Dave MacDonald.

S f D t

Page 26: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 26/41

   ©

   A   B   B   G  r  o  u  p  -   2   6  -

   2   1  -   M  a  r  -   0   7

Sources of Data

Manufacturer’s data Based on either returned goods or predictions using either 

FMEA (failure mode effects analysis) or 

FMEDA (failure mode effects and diagnostic analysis) These should not be confused with real field failure rates based

on actual use of the units

Field data (61511 uses term prior use)

Based on similar operating conditions and environment

Should be collected using a methodical / auditable process andallow for errors (misreporting / non reporting) in the collection of

the data

Generic data

From an extensive history of similar industries found to be

appropriate

‘Ch ki ’ th b

Page 27: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 27/41

   ©

   A   B   B   G  r  o  u  p  -   2   7  -

   2   1  -   M  a  r  -   0   7

‘Checking’ the numbers

IEC 61511 architectural constraints

Hardware Fault Tolerance

Designed to verify that the ‘numbers’ make sense No mathematical basis for the figures

Based on experience

Specified SIL can be reduced with operationalexperience and analysis

 Analyser Trip Amp

Relay Logic

Solenoid Trip Valve

 Analyser Trip Amp Solenoid Trip Valve

Constraint Hardware Fault Tolerance (1)

Page 28: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 28/41

   ©

   A   B   B   G  r  o  u  p  -   2   8  -

   2   1  -   M  a  r  -   0   7

Constraint - Hardware Fault Tolerance (1)

Used for sensor, final elements and non PE Logic Solver  Table 6 in IEC61511 Part 1

Increased fault tolerance can enable easier maintenance and

testing

Constraint Hardware Fault Tolerance (2)

Page 29: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 29/41

   ©

   A   B   B   G  r  o  u  p  -   2   9  -

   2   1  -   M  a  r  -   0   7

Constraint - Hardware Fault Tolerance (2)

 Applies to PE Logic Solvers

Table 5 in IEC 61511 Part 1

The ‘cleverer’ the PES, the less fault tolerance required for the

target SIL

More complex tables in IEC61508 – used

for certified instruments to reduce HFT

Manufacturer’s Data E l 2

Page 30: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 30/41

   ©

   A   B   B   G  r  o  u  p  -   3   0  -

   2   1  -   M  a  r  -   0   7

Manufacturer’s Data – Example 2

Non Hardware faults Systematic

Page 31: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 31/41

   ©

   A   B   B   G  r

  o  u  p  -   3   1  -

   2   1  -   M  a  r  -   0   7

Non-Hardware faults - Systematic

Because of the findings from ‘Out of Control’ and otherwork…

Large number of faults are not caused by hardware

We need appropriate processes, procedures, methods –‘systems’ in place to control these faults

Specification

43%

Changes after

commissioning

21%

Installation &

commissioning

6%

Operation &

maintenance

15%Design &

implementation

15%

Problems with software systematic faults

Page 32: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 32/41

   ©

   A   B   B   G  r

  o  u  p  -   3   2  -

   2   1  -   M  a  r  -   0   7

Problems with software – systematic faults

How do you make software 10 times better?

How do you measure software?

What is the probability of Fail to Danger (pfd) of a lumpof code?

You cannot measure software like hardware –

quantitative methods

You have to use more rigorous techniques for softwarerequired for higher level SIL – qualitative methods

Example of Software Techniques

Page 33: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 33/41

   ©

   A   B   B   G  r

  o  u  p  -   3   3  -

   2   1  -   M  a  r  -   0   7

Technique/Measures Ref SIL 1 SIL 2 SIL 3 SIL 4

1a Structured methods including for example,

JSD, MASCOT,SADT and Yourdon

C.2.1. HR HR HR HR  

1b Semi-formal methods Table B.7 R HR HR HR  1c Formal methods including for example, CCS,

CSP, HOL, LOTOS, OBJ, temporal logic,

VDM and Z

C.2.4

-- R R HR  

2 Computer-aided design tools B.3.5 R R HR HR  

3 Defensive programming C.2.5 -- R HR HR  

4 Modular approach Table B.9 HR HR HR HR  

5 Design and coding standards Table B.1 R HR HR HR  

6 Structured programming C.2.7 HR HR HR HR  

7 Use of trusted/verified software modules and components (if available) C.2.10C.4.5 R HR HR HR  

Table A.4 - Software design and development: detailed design

Example of Software Techniques

Summary of Step 2

Page 34: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 34/41

   ©

   A   B   B   G  r

  o  u  p  -   3   4  -

   2   1  -   M  a  r  -   0   7

Summary of Step 2

80% - 90% of safety functions should be SIL1 Single channel, reasonable test intervals, no HFT to consider 

High SIL, complex architecture

Use a specialist

Shorter test intervals (simple SIL calculations may not apply)

 Additional hardware (including final elements)

Common cause faults, hardware fault tolerance, SFF, DC

Systematic controls

Take care with instrument data

Field data is best

Manufacturers data is a prediction, will need to be adjusted for plant conditions

Step 3 – Operate and Maintain to meet the SIL

Page 35: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 35/41

   ©

   A   B   B   G  r

  o  u  p  -   3   5  -

   2   1  -   M  a  r  -   0   7

Step 3 Operate and Maintain to meet the SIL

Design & Development

of other means of risk

reduction

Hazard and Risk Assessment1

Allocation of safety functions

to protection layers2

Safety Requirementsspecification for the safety

instrumented system3

Design & Engineering of

Safety Instrumented System

4

Installation, Commissioning

and Validation5

Operation and Maintenance6

Modification7

Decommissioning8

M an a g em en t  

 of  f   un c t  i   on al   s af   e t   y an d f   un c t  i   on al   s af   e t   y

 a s s e s sm en t   an d  a u d i   t  i  n g

10

 S  af   e t   y

L i  f   e- C  y cl   e s t  r  u c t   ur  e an d  pl   anni  n g

11

Verification

9

IEC61511 Safety Lifecycle

Operation and Maintenance

Page 36: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 36/41

   ©

   A   B   B   G  r  o  u  p  -   3   6  -

   2   1  -   M  a  r  -   0   7

Operation and Maintenance

What activities are required to ensure the SafetyInstrumented System keeps meeting the target SIL?

What operations and test data needs to be kept and

recorded to verify SIL determination and Design

assumptions?

Proof Tests – 61511 states…

Page 37: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 37/41

   ©

   A   B   B   G  r  o  u  p  -   3   7  -

   2   1  -   M  a  r  -   0   7

Proof Tests 61511 states…

Periodic proof tests shall be conductedusing a written procedure

The entire SIS shall be tested including the

sensor(s), the logic solver and the finalelement(s)

Different parts of the SIS may require different

test intervals

The frequency of the proof tests shall be

decided using the PFDavg calculation

 At some periodic interval the frequency ofthe testing shall be re-evaluated.

Why record Demands?

Page 38: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 38/41

   ©

   A   B   B   G  r  o  u  p  -   3   8  -

   2   1  -   M  a  r  -   0   7

Why record Demands?

To demonstrate the design demand rate is notbeing exceeded

To demonstrate that the causes of demand

are as expected

To check causes and rates of failsafe

demands

To be able to carry out periodic reviews

Why record Proof Test Records/Results?

Page 39: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 39/41

   ©

   A   B   B   G  r  o  u  p  -   3   9  -

   2   1  -   M  a  r  -   0   7

y

To demonstrate that testing is beingcarried out at specified interval

 As an auditable trail to the recorded

results

To indicate who carried out the tests

To demonstrate that faults found havebeen rectified

To be able to carry out periodic reviews

Need to record results in a manner whichenables the results to be extracted/

presented in a format which makes

reviews possible

Summary of the 3 steps

Page 40: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 40/41

   ©

   A   B   B   G  r  o  u  p  -   4   0  -

   2   1  -   M  a  r  -   0   7

y p

Get the Target SIL correct Save time, money, equipment, maintenance

Design to meet the SIL

More than failure rates

Where do you get failure data from?

Hardware Fault Tolerance and Systematic controls

Operate and Maintain to keep the SIL

Testing

Recording

 Analysing and improving

Page 41: AstraZeneca+SIL+Presentation

7/18/2019 AstraZeneca+SIL+Presentation

http://slidepdf.com/reader/full/astrazenecasilpresentation 41/41